About this trial
There are currently no early predictive biomarkers for severity of acute pancreatitis (AP) that would allow stratification of patients for potential early interventional therapies. Hyperglycaemia is frequently observed to accompany and contribute to severe AP. However, the underlying mechanism is multifactorial, including in the acute phase of injury, where elevated adrenaline, cortisol and glucagon and inflammatory cytokine-induced insulin resistance all contribute to hyperglycaemia. The investigators propose that the extent of collateral injury of pancreatic β-cells and consequent loss of insulin secretion during the course of acute pancreatitis (AP) underlies disease severity. The investigators will measure plasma C-peptide (as a reliable readout of endogenous insulin), with moment-to-moment glucose monitoring (using subcutaneous continuous glucose monitoring devices), and bacterial endotoxin (lipopolysaccharide (LPS) in a prospective cohort of 30 severe AP patient blood samples taken every 5 days for up to 5 weeks of hospitalization.
Eligibility criteria
Qualifiers
Age 18 years or over
Admission diagnosis of acute pancreatitis (based on Revised Atlanta Criteria)
Ability to provide informed consent in English
Disqualifiers
Known diabetes mellitus
Use of insulin therapy before admission
Pregnancy
Contraindications to CGM (e.g., allergy to device adhesive)
Trial design
Treatments tested in this trial
- Not listed